--- title: "Fasoracetam (NS-105): Dosing & Vendor Prices" description: "Fasoracetam (NS-105): dosing protocols, mechanism & side effects. Compare 1 verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Fasoracetam (NS-105)" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "Fasoracetam (NS-105)", "description": "Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia. That program did not lead to approval anywhere. The molecule was later licensed and revived in the United States as NFC-1 and then AEVI-001 by Aevi Genomic Medicine, which tested it in children and adolescents with attention deficit hyperactivity disorder selected by genotype, and more recently as NB-001 by Nobias Therapeutics for 22q11.2 deletion syndrome. No regulator has approved it for any indication. Material sold to consumers is a research chemical, usually the monohydrate, and the chemistry values below are for the anhydrous form. The Nippon Shinyaku pharmacology, published between 1997 and 2000, describes a compound acting through metabotropic glutamate receptors rather than through a single ion channel. In rat cerebrocortical membranes, NS-105 inhibited forskolin-stimulated cyclic AMP formation through pertussis toxin sensitive G proteins and enhanced it after pertussis toxin pretreatment, a bidirectional pattern shared with the metabotropic glutamate agonist ACPD and blocked by a metabotropic glutamate antagonist (PMID: 9134967). The same bidirectional effect appeared in cultured mouse cortical neurons (PMID: 9272724), and antisense work assigned the inhibitory arm to group II and group III receptors and the facilitatory arm to group I (PMID: 10633154). Two other effects are reported: repeated dosing increased GABA-B receptor numbers in rat cerebral cortex without changing beta-adrenoceptor or 5-HT2 binding (PMID: 9424016), and NS-105 increased acetylcholine release and high-affinity choline uptake in rat cerebral cortex (PMID: 10494996). In rats, NS-105 reversed memory disruption produced by scopolamine, by lesions of the nucleus basalis magnocellularis, by AF64A, by baclofen, by cerebral ischemia and by electroconvulsive shock (PMID: 10494996). It also reduced immobility in the forced swim test and reversed escape failure in learned helplessness (PMID: 9424016). The human data are thin and mostly open-label. A five-week open-label study with a single-blind placebo week enrolled 30 adolescents aged 12 to 17 who had ADHD and mutations in metabotropic glutamate receptor network genes. Mean Clinical Global Impressions scores improved from 3.79 to 2.33 for improvement and 4.83 to 3.86 for severity, both significant, and adverse event rates during the placebo week did not differ from active weeks (PMID: 29339723). The controlled trials that followed did not confirm this. The ASCEND phase 2 program, run in two parts in children and adolescents with and without the relevant copy number variants, completed in 2018 (NCT03265119; NCT03609619) and posted results show the primary ADHD rating scale endpoint was not met in either part, with placebo numerically ahead in Part A and the drug described as safe and well tolerated. A separate placebo-controlled crossover trial in 37 children and adolescents with 22q11 deletion syndrome completed in 2023 (NCT05290493). Fasoracetam is not approved in any country and is not a controlled substance in the United States. It is a research-use-only compound in the United States market.", "url": "https://www.bodyhackguide.co/compound/fasoracetam", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "49.99", "highPrice": "49.99", "priceCurrency": "USD", "offerCount": "1", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "49.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/fasoracetam/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" } } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Fasoracetam (NS-105)", "description": "Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia. That program did not lead to approval anywhere. The molecule was later licensed and revived in the United States as NFC-1 and then AEVI-001 by Aevi Genomic Medicine, which tested it in children and adolescents with attention deficit hyperactivity disorder selected by genotype, and more recently as NB-001 by Nobias Therapeutics for 22q11.2 deletion syndrome. No regulator has approved it for any indication. Material sold to consumers is a research chemical, usually the monohydrate, and the chemistry values below are for the anhydrous form. The Nippon Shinyaku pharmacology, published between 1997 and 2000, describes a compound acting through metabotropic glutamate receptors rather than through a single ion channel. In rat cerebrocortical membranes, NS-105 inhibited forskolin-stimulated cyclic AMP formation through pertussis toxin sensitive G proteins and enhanced it after pertussis toxin pretreatment, a bidirectional pattern shared with the metabotropic glutamate agonist ACPD and blocked by a metabotropic glutamate antagonist (PMID: 9134967). The same bidirectional effect appeared in cultured mouse cortical neurons (PMID: 9272724), and antisense work assigned the inhibitory arm to group II and group III receptors and the facilitatory arm to group I (PMID: 10633154). Two other effects are reported: repeated dosing increased GABA-B receptor numbers in rat cerebral cortex without changing beta-adrenoceptor or 5-HT2 binding (PMID: 9424016), and NS-105 increased acetylcholine release and high-affinity choline uptake in rat cerebral cortex (PMID: 10494996). In rats, NS-105 reversed memory disruption produced by scopolamine, by lesions of the nucleus basalis magnocellularis, by AF64A, by baclofen, by cerebral ischemia and by electroconvulsive shock (PMID: 10494996). It also reduced immobility in the forced swim test and reversed escape failure in learned helplessness (PMID: 9424016). The human data are thin and mostly open-label. A five-week open-label study with a single-blind placebo week enrolled 30 adolescents aged 12 to 17 who had ADHD and mutations in metabotropic glutamate receptor network genes. Mean Clinical Global Impressions scores improved from 3.79 to 2.33 for improvement and 4.83 to 3.86 for severity, both significant, and adverse event rates during the placebo week did not differ from active weeks (PMID: 29339723). The controlled trials that followed did not confirm this. The ASCEND phase 2 program, run in two parts in children and adolescents with and without the relevant copy number variants, completed in 2018 (NCT03265119; NCT03609619) and posted results show the primary ADHD rating scale endpoint was not met in either part, with placebo numerically ahead in Part A and the drug described as safe and well tolerated. A separate placebo-controlled crossover trial in 37 children and adolescents with 22q11 deletion syndrome completed in 2023 (NCT05290493). Fasoracetam is not approved in any country and is not a controlled substance in the United States. It is a research-use-only compound in the United States market.", "lastReviewed": "2026-09-07T04:50:55.210Z", "url": "https://www.bodyhackguide.co/compound/fasoracetam", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Fasoracetam (NS-105)", "alternateName": [ "NS-105", "NFC-1", "AEVI-001", "LAM-105", "NB-001", "Fasoracetam monohydrate", "5-oxo-D-prolinepiperidinamide" ], "description": "Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia. That program did not lead to approval anywhere. The molecule was later licensed and revived in the United States as NFC-1 and then AEVI-001 by Aevi Genomic Medicine, which tested it in children and adolescents with attention deficit hyperactivity disorder selected by genotype, and more recently as NB-001 by Nobias Therapeutics for 22q11.2 deletion syndrome. No regulator has approved it for any indication. Material sold to consumers is a research chemical, usually the monohydrate, and the chemistry values below are for the anhydrous form. The Nippon Shinyaku pharmacology, published between 1997 and 2000, describes a compound acting through metabotropic glutamate receptors rather than through a single ion channel. In rat cerebrocortical membranes, NS-105 inhibited forskolin-stimulated cyclic AMP formation through pertussis toxin sensitive G proteins and enhanced it after pertussis toxin pretreatment, a bidirectional pattern shared with the metabotropic glutamate agonist ACPD and blocked by a metabotropic glutamate antagonist (PMID: 9134967). The same bidirectional effect appeared in cultured mouse cortical neurons (PMID: 9272724), and antisense work assigned the inhibitory arm to group II and group III receptors and the facilitatory arm to group I (PMID: 10633154). Two other effects are reported: repeated dosing increased GABA-B receptor numbers in rat cerebral cortex without changing beta-adrenoceptor or 5-HT2 binding (PMID: 9424016), and NS-105 increased acetylcholine release and high-affinity choline uptake in rat cerebral cortex (PMID: 10494996). In rats, NS-105 reversed memory disruption produced by scopolamine, by lesions of the nucleus basalis magnocellularis, by AF64A, by baclofen, by cerebral ischemia and by electroconvulsive shock (PMID: 10494996). It also reduced immobility in the forced swim test and reversed escape failure in learned helplessness (PMID: 9424016). The human data are thin and mostly open-label. A five-week open-label study with a single-blind placebo week enrolled 30 adolescents aged 12 to 17 who had ADHD and mutations in metabotropic glutamate receptor network genes. Mean Clinical Global Impressions scores improved from 3.79 to 2.33 for improvement and 4.83 to 3.86 for severity, both significant, and adverse event rates during the placebo week did not differ from active weeks (PMID: 29339723). The controlled trials that followed did not confirm this. The ASCEND phase 2 program, run in two parts in children and adolescents with and without the relevant copy number variants, completed in 2018 (NCT03265119; NCT03609619) and posted results show the primary ADHD rating scale endpoint was not met in either part, with placebo numerically ahead in Part A and the drug described as safe and well tolerated. A separate placebo-controlled crossover trial in 37 children and adolescents with 22q11 deletion syndrome completed in 2023 (NCT05290493). Fasoracetam is not approved in any country and is not a controlled substance in the United States. It is a research-use-only compound in the United States market.", "activeIngredient": "Fasoracetam (NS-105)", "administrationRoute": "Oral", "mechanismOfAction": "Fasoracetam acts on metabotropic glutamate receptors and modulates adenylyl cyclase in both directions. In rat cerebrocortical membranes it inhibited forskolin-stimulated cyclic AMP formation through pertussis toxin sensitive G proteins and enhanced cyclic AMP formation after pertussis toxin pretreatment, an effect abolished by cholera toxin and mimicked by the metabotropic glutamate agonist ACPD but blocked by a metabotropic glutamate antagonist (PMID: 9134967). Antisense knockdown assigned the inhibitory action to group II and group III receptors and the facilitatory action to group I (PMID: 10633154). Two downstream effects are reported in rats: repeated administration increased the number of GABA-B receptors in cerebral cortex without changing beta-adrenoceptor or 5-HT2 binding (PMID: 9424016), and single dosing increased cortical acetylcholine release and high-affinity choline uptake in cortex and hippocampus without changing choline acetyltransferase activity (PMID: 10494996).", "dosageForm": "capsule", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is Fasoracetam (NS-105) used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia. That program did not lead to approval anywhere. The molecule was later licensed and revived in the United States as NFC-1 and then AEVI-001 by Aevi Genomic Medicine, which tested it in children and adolescents with attention deficit hyperactivity disorder selected by genotype, and more recently as NB-001 by Nobias Therapeutics for 22q11.2 deletion syndrome. No regulator has approved it for any indication. Material sold to consumers is a research chemical, usually the monohydrate, and the chemistry values below are for the anhydrous form. The Nippon Shinyaku pharmacology, published between 1997 and 2000, describes a compound acting through metabotropic glutamate receptors rather than through a single ion channel. In rat cerebrocortical membranes, NS-105 inhibited forskolin-stimulated cyclic AMP formation through pertussis toxin sensitive G proteins and enhanced it after pertussis toxin pretreatment, a bidirectional pattern shared with the metabotropic glutamate agonist ACPD and blocked by a metabotropic glutamate antagonist (PMID: 9134967). The same bidirectional effect appeared in cultured mouse cortical neurons (PMID: 9272724), and antisense work assigned the inhibitory arm to group II and group III receptors and the facilitatory arm to group I (PMID: 10633154). Two other effects are reported: repeated dosing increased GABA-B receptor numbers in rat cerebral cortex without changing beta-adrenoceptor or 5-HT2 binding (PMID: 9424016), and NS-105 increased acetylcholine release and high-affinity choline uptake in rat cerebral cortex (PMID: 10494996). In rats, NS-105 reversed memory disruption produced by scopolamine, by lesions of the nucleus basalis magnocellularis, by AF64A, by baclofen, by cerebral ischemia and by electroconvulsive shock (PMID: 10494996). It also reduced immobility in the forced swim test and reversed escape failure in learned helplessness (PMID: 9424016). The human data are thin and mostly open-label. A five-week open-label study with a single-blind placebo week enrolled 30 adolescents aged 12 to 17 who had ADHD and mutations in metabotropic glutamate receptor network genes. Mean Clinical Global Impressions scores improved from 3.79 to 2.33 for improvement and 4.83 to 3.86 for severity, both significant, and adverse event rates during the placebo week did not differ from active weeks (PMID: 29339723). The controlled trials that followed did not confirm this. The ASCEND phase 2 program, run in two parts in children and adolescents with and without the relevant copy number variants, completed in 2018 (NCT03265119; NCT03609619) and posted results show the primary ADHD rating scale endpoint was not met in either part, with placebo numerically ahead in Part A and the drug described as safe and well tolerated. A separate placebo-controlled crossover trial in 37 children and adolescents with 22q11 deletion syndrome completed in 2023 (NCT05290493). Fasoracetam is not approved in any country and is not a controlled substance in the United States. It is a research-use-only compound in the United States market." } }, { "@type": "Question", "name": "What forms does Fasoracetam (NS-105) come in?", "acceptedAnswer": { "@type": "Answer", "text": "Fasoracetam (NS-105) is available in capsule form." } }, { "@type": "Question", "name": "How much does Fasoracetam (NS-105) cost?", "acceptedAnswer": { "@type": "Answer", "text": "Prices start at $49.99 across 1 verified vendor." } }, { "@type": "Question", "name": "How do I compare Fasoracetam (NS-105) vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Ffasoracetam) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. Fasoracetam (NS-105) [Where to buy Fasoracetam (NS-105)](/buy/fasoracetam) [Fasoracetam (NS-105) coupon codes](/coupons/fasoracetam) [Fasoracetam (NS-105) protocol](/protocol/fasoracetam) [Alternatives to Fasoracetam (NS-105)](/alternatives-to/fasoracetam) [Fasoracetam (NS-105) side effects](/side-effects/fasoracetam) 1. [Home](/) 3. [Compounds](/compare) 5. Fasoracetam (NS-105) ![Fasoracetam (NS-105) molecular structure](/assets/peptide-structure-placeholder-DUmZBF_j.png) # Fasoracetam (NS-105) Nootropics Phase 2 Download PDF Also known as: NS-105, NFC-1, AEVI-001, LAM-105, NB-001, Fasoracetam monohydrate, 5-oxo-D-prolinepiperidinamide Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia. That program did not lead to approval anywhere. Half-Life: Mean terminal half-life 4.82 hours, range 4.06 to 6.99 hours, after single oral doses in adolescents aged 12 to 17, with the drug excreted for the most part unchanged through the kidneys (PMID: 29339723). After intravenous dosing in animals, elimination half-life was 0.67 hours in rats, 2.1 hours in dogs and 1.3 hours in monkeys, with high systemic availability after oral dosing in all three species (PMID: 10604039). Route: Oral MW: 196.25 g/mol CAS: 110958-19-5 Last reviewed: Sep 7, 2026 [ Nootropics Category ](/wiki#cat-nootropics) Phase 2 Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare Prices1 Related ## Overview ### Best Price Available ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $49.99 60 capsules · capsule [Buy Now](https://disguisedalpha.com/product/fasoracetam/?coupon=reddit) Compare 1 vendor ### At A Glance Mechanism Fasoracetam acts on metabotropic glutamate receptors and modulates adenylyl cyclase in both directions. In rat cerebrocortical membranes it inhibited forskolin-stimulated cyclic AMP formation through pertussis toxin sensitive G proteins and enhanced cyclic AMP formation after per… Half-Life Mean terminal half-life 4.82 hours, range 4.06 to 6.99 hours, after single oral doses in adolescents aged 12 to 17, with the drug excreted for the most part unchanged through the kidneys (PMID: 29339723). After intravenous dosing in animals, elimination half-life was 0.67 hours in rats, 2.1 hours in dogs and 1.3 hours in monkeys, with high systemic availability after oral dosing in all three species (PMID: 10604039). Routes Oral Potential Benefits Reversed memory disruption from scopolamine, nucleus basalis lesion, AF64A, baclofen, cerebral ischemia and electroconvulsive shock in rats (PMID: 10494996) Increased acetylcholine release and high-affinity choline uptake in the cerebral cortex and hippocampus of rats (PMID: 10494996) Reduced immobility in the forced swim test and reversed escape failure in learned helplessness in rats (PMID: 9424016) Improved Clinical Global Impressions improvement and severity scores over five weeks in 30 adolescents with ADHD and metabotropic glutamate receptor network mutations, in an open-label study with a single-blind placebo week (PMID: 29339723) ### Overview Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia. That program did not lead to approval anywhere. The molecule was later licensed and revived in the United States as NFC-1 and then AEVI-001 by Aevi Genomic Medicine, which tested it in children and adolescents with attention deficit hyperactivity disorder selected by genotype, and more recently as NB-001 by Nobias Therapeutics for 22q11.2 deletion syndrome. No regulator has approved it for any indication. Material sold to consumers is a research chemical, usually the monohydrate, and the chemistry values below are for the anhydrous form. The Nippon Shinyaku pharmacology, published between 1997 and 2000, describes a compound acting through metabotropic glutamate receptors rather than through a single ion channel. In rat cerebrocortical membranes, NS-105 inhibited forskolin-stimulated cyclic AMP formation through pertussis toxin sensitive G proteins and enhanced it after pertussis toxin pretreatment, a bidirectional pattern shared with the metabotropic glutamate agonist ACPD and blocked by a metabotropic glutamate antagonist (PMID: 9134967). The same bidirectional effect appeared in cultured mouse cortical neurons (PMID: 9272724), and antisense work assigned the inhibitory arm to group II and group III receptors and the facilitatory arm to group I (PMID: 10633154). Two other effects are reported: repeated dosing increased GABA-B receptor numbers in rat cerebral cortex without changing beta-adrenoceptor or 5-HT2 binding (PMID: 9424016), and NS-105 increased acetylcholine release and high-affinity choline uptake in rat cerebral cortex (PMID: 10494996). In rats, NS-105 reversed memory disruption produced by scopolamine, by lesions of the nucleus basalis magnocellularis, by AF64A, by baclofen, by cerebral ischemia and by electroconvulsive shock (PMID: 10494996). It also reduced immobility in the forced swim test and reversed escape failure in learned helplessness (PMID: 9424016). The human data are thin and mostly open-label. A five-week open-label study with a single-blind placebo week enrolled 30 adolescents aged 12 to 17 who had ADHD and mutations in metabotropic glutamate receptor network genes. Mean Clinical Global Impressions scores improved from 3.79 to 2.33 for improvement and 4.83 to 3.86 for severity, both significant, and adverse event rates during the placebo week did not differ from active weeks (PMID: 29339723). The controlled trials that followed did not confirm this. The ASCEND phase 2 program, run in two parts in children and adolescents with and without the relevant copy number variants, completed in 2018 (NCT03265119; NCT03609619) and posted results show the primary ADHD rating scale endpoint was not met in either part, with placebo numerically ahead in Part A and the drug described as safe and well tolerated. A separate placebo-controlled crossover trial in 37 children and adolescents with 22q11 deletion syndrome completed in 2023 (NCT05290493). Fasoracetam is not approved in any country and is not a controlled substance in the United States. It is a research-use-only compound in the United States market. ### Potential Research Fields Metabotropic glutamate signaling ADHD Cognitive enhancement Nootropics ## Chemical Information IUPAC Name Not yet available CAS Number 110958-19-5 Molecular Formula C10H16N2O2 Molecular Mass 196.25 g/mol (anhydrous) ![Fasoracetam (NS-105) molecular structure](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/198695/PNG) [View on PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/198695) ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications No formal contraindications have been established. Fasoracetam is excreted mostly unchanged through the kidneys (PMID: 29339723), so reduced renal function would be expected to raise exposure. In rats, radiolabeled NS-105 transferred into the fetus and into milk after a single oral dose (PMID: 10635441), which is a mechanism-based reason to avoid use in pregnancy and lactation. Repeated administration increased GABA-B receptor numbers in rat cerebral cortex (PMID: 9424016), so the pharmacology of repeated exposure is not the same as that of a single dose. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $49.99 Best $/mg — Vendors 1 Listings 1 capsule [Sign in for alerts ](/auth) Form Allcapsule Sort Price $/mg Vendor Vendor Product Form Qty Price $/mg Coupon ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) [Disguised Alpha](/vendor/disguised-alpha) [50 ](/vendor-trust-scorecard) 🇺🇸 US 🇪🇺 EU 🇬🇧 UK Fasoracetam capsules (60) capsule 60 capsules ● In Stock $49.99 BEST — — [Buy](https://disguisedalpha.com/product/fasoracetam/?coupon=reddit) Get Fasoracetam (NS-105) Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. Current lowest: $49.99 [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Fasoracetam (NS-105). [Sign in](/auth) Current low $49.99 as of Sep 7, 2026 7-day low $49.99 30-day low $49.99 30-day change — baseline building Tracking since Sep 7, 2026 · 1 data point ### Vendors Selling Fasoracetam (NS-105) [ ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) #### Disguised Alpha 1 listing · from $49.99 ](/vendor/disguised-alpha) How we score these vendors Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. [View Scorecard](/vendors/scorecard) ### Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Aniracetam Nootropics Approved (Italy) Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057. t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694). Preclinical View Profile ](/compound/aniracetam)[ ### Bemethyl (bemitil) Nootropics Approved (Russia) Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt. t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773) Preclinical View Profile ](/compound/bemethyl)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Cyclazodone Nootropics Preclinical Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. Preclinical View Profile ](/compound/cyclazodone)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa) [ View Full Dosage Guide → Protocols, calculator & safety for Fasoracetam (NS-105) ](/guides/dosage/fasoracetam) ### Best Price ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $49.99 [Buy Now](https://disguisedalpha.com/product/fasoracetam/?coupon=reddit) 1 vendors · 1 listings ### Research Score 30 0 PubMed studies ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings ### Quick Facts Half-Life Mean terminal half-life 4.82 hours, range 4.06 to 6.99 hours, after single oral doses in adolescents aged 12 to 17, with the drug excreted for the most part unchanged through the kidneys (PMID: 29339723). After intravenous dosing in animals, elimination half-life was 0.67 hours in rats, 2.1 hours in dogs and 1.3 hours in monkeys, with high systemic availability after oral dosing in all three species (PMID: 10604039). Molecular Weight 196.25 g/mol (anhydrous) Administration Oral CAS Number 110958-19-5 Trial Phase Phase 2 0 [Full Dosage Guide](/guides/dosage/fasoracetam)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is Fasoracetam (NS-105) used for in research? Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia. That program did not lead to approval anywhere. The molecule was later licensed and revived in the United States as NFC-1 and then AEVI-001 by Aevi Genomic Medicine, which tested it in children and adolescents with attention deficit hyperactivity disorder selected by genotype, and more recently as NB-001 by Nobias Therapeutics for 22q11.2 deletion syndrome. No regulator has approved it for any indication. Material sold to consumers is a research chemical, usually the monohydrate, and the chemistry values below are for the anhydrous form. The Nippon Shinyaku pharmacology, published between 1997 and 2000, describes a compound acting through metabotropic glutamate receptors rather than through a single ion channel. In rat cerebrocortical membranes, NS-105 inhibited forskolin-stimulated cyclic AMP formation through pertussis toxin sensitive G proteins and enhanced it after pertussis toxin pretreatment, a bidirectional pattern shared with the metabotropic glutamate agonist ACPD and blocked by a metabotropic glutamate antagonist (PMID: 9134967). The same bidirectional effect appeared in cultured mouse cortical neurons (PMID: 9272724), and antisense work assigned the inhibitory arm to group II and group III receptors and the facilitatory arm to group I (PMID: 10633154). Two other effects are reported: repeated dosing increased GABA-B receptor numbers in rat cerebral cortex without changing beta-adrenoceptor or 5-HT2 binding (PMID: 9424016), and NS-105 increased acetylcholine release and high-affinity choline uptake in rat cerebral cortex (PMID: 10494996). In rats, NS-105 reversed memory disruption produced by scopolamine, by lesions of the nucleus basalis magnocellularis, by AF64A, by baclofen, by cerebral ischemia and by electroconvulsive shock (PMID: 10494996). It also reduced immobility in the forced swim test and reversed escape failure in learned helplessness (PMID: 9424016). The human data are thin and mostly open-label. A five-week open-label study with a single-blind placebo week enrolled 30 adolescents aged 12 to 17 who had ADHD and mutations in metabotropic glutamate receptor network genes. Mean Clinical Global Impressions scores improved from 3.79 to 2.33 for improvement and 4.83 to 3.86 for severity, both significant, and adverse event rates during the placebo week did not differ from active weeks (PMID: 29339723). The controlled trials that followed did not confirm this. The ASCEND phase 2 program, run in two parts in children and adolescents with and without the relevant copy number variants, completed in 2018 (NCT03265119; NCT03609619) and posted results show the primary ADHD rating scale endpoint was not met in either part, with placebo numerically ahead in Part A and the drug described as safe and well tolerated. A separate placebo-controlled crossover trial in 37 children and adolescents with 22q11 deletion syndrome completed in 2023 (NCT05290493). Fasoracetam is not approved in any country and is not a controlled substance in the United States. It is a research-use-only compound in the United States market. What forms does Fasoracetam (NS-105) come in? Fasoracetam (NS-105) is available in capsule form. How much does Fasoracetam (NS-105) cost? Prices start at $49.99 across 1 verified vendor. How do I compare Fasoracetam (NS-105) vendors? Compare prices, payment methods, shipping, and COA scores across 1 vendor. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Aniracetam Nootropics Approved (Italy) Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057. t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694). Preclinical View Profile ](/compound/aniracetam)[ ### Bemethyl (bemitil) Nootropics Approved (Russia) Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt. t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773) Preclinical View Profile ](/compound/bemethyl)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Cyclazodone Nootropics Preclinical Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. Preclinical View Profile ](/compound/cyclazodone)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-fasoracetam) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋